Molecule

S2460 

Biological Activity:
Pramipexole (Mirapex) is a partial/full D2S, D2L, D3, D4 receptor agonist with a Ki of 3.9, 2.2, 0.5 and 5.1 nM for D2S, D2L, D3, D4 receptor, respectively. Pramipexole (Mirapex) also possesses low/insignificant affinity (500-10,000 nM) for the 5-HT1A, 5-HT1B, 5-HT1D, and α2-adrenergic receptors. Pramipexole (Mirapex) has negligible affinity (>10,000 nM) for the D1, D5, 5-HT2, α1-adrenergic, β-adrenergic, H1, and mACh receptors. Pramipexole (Mirapex) is a non-ergoline dopamine agonist revealed for treating early-stage Parkinson’s disease (PD) and restless legs syndrome (RLS). [1][2][3]References on Pramipexole (Mirapex)[1] http://en.wikipedia.org/wiki/Pramipexole, , [2] Clin Ther., 2006 Aug, 28(8):1065-78.[3] J Pharmacol Exp Ther., 2002 Nov, 303(2):805-14.

P700750 

(S)-Pramipexole enantiomer. A dopamine-D2-receptor agonist. Antiparkinsonian. Pramipexole (Mirapex, Mirapexin, Sifrol) is a non-ergoline dopamine agonist indicated for treating early-stage Parkinson's disease (PD) and restless legs syndrome (RLS).[1] It i

P700755 

A dopamine-D2-receptor agonist. Antiparkinsonian.

CHEBI:8356 

A member of the class of benzothiazoles that is 4,5,6,7-tetrahydro-1,3-benzothiazole in which the hydrogens at the 2 and 6-pro-S-positions are substituted by amino and propylamino groups, respectively.